$PULM
Pulmatrix Inc Stock $pulm

$pulm Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000119312515374719 Filed on November 12, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q3
Revenue	$280.0K	$651.0K	$30.00K
YoY Change		2070.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.100M	$3.120M	$1.086M
YoY Change	91.43%	187.29%	117.64%
% of Gross Profit
Research & Development	$2.470M	$2.193M	$1.929M
YoY Change	299.03%	13.69%	289.7%
% of Gross Profit
Depreciation & Amortization	$50.00K	$60.00K	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$4.570M	$5.312M	$2.624M
YoY Change	166.32%	102.44%	163.98%
Operating Profit		-$4.661M	-$2.594M
YoY Change		79.68%	160.97%
Interest Expense	-$220.0K	$220.0K	$7.885M
YoY Change		-97.21%
% of Operating Profit
Other Income/Expense, Net	-$20.00K	-$51.00K	$5.000K
YoY Change	-600.0%	-1120.0%
Pretax Income	-$4.540M	-$4.930M	-$1.710M
YoY Change	165.5%	188.3%	72.73%
Income Tax
% Of Pretax Income
Net Earnings	-$4.540M	-$4.932M	-$11.13M
YoY Change	165.19%	-55.7%	1020.12%
Net Earnings / Revenue	-1621.43%	-757.6%	-37113.33%
Basic Earnings Per Share
Diluted Earnings Per Share	-$3.068M	-$3.354M	-$9.000M
COMMON SHARES
Basic Shares Outstanding	14.52M shares	14.52M shares	4.804M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.90M	$22.03M	$12.88M
YoY Change	63.35%	71.04%	14211.11%
Cash & Equivalents	$18.90M	$22.03M	$753.0K
Short-Term Investments
Other Short-Term Assets	$206.0K	$1.330M	$20.00K
YoY Change	312.0%	6550.0%	-90.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$20.46M	$23.36M	$13.17M
YoY Change	2362.33%	77.38%	4289.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$685.0K	$558.0K	$105.0K
YoY Change	45.74%	431.43%
Goodwill	$15.94M	$15.94M
YoY Change
Intangibles	$7.534M	$7.534M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$250.0K	$18.00K
YoY Change
Total Long-Term Assets	$24.41M	$24.31M	$105.0K
YoY Change	3290.42%	23047.62%	-87.2%
TOTAL ASSETS
Total Short-Term Assets	$20.46M	$23.36M	$13.17M
Total Long-Term Assets	$24.41M	$24.31M	$105.0K
Total Assets	$44.87M	$47.66M	$13.27M
YoY Change	2793.17%	259.08%	1085.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.090M	$927.0K
YoY Change	404.63%
Accrued Expenses	$1.486M	$1.135M	$570.0K
YoY Change	-58.07%	99.12%	612.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.029M	$413.0K
YoY Change
Total Short-Term Liabilities	$3.605M	$2.475M	$575.0K
YoY Change	-91.71%	330.43%	-56.77%
LONG-TERM LIABILITIES
Long-Term Debt	$5.692M	$6.313M	$0.00
YoY Change
Other Long-Term Liabilities	$10.00K	$10.00K
YoY Change
Total Long-Term Liabilities	$5.692M	$6.313M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.605M	$2.475M	$575.0K
Total Long-Term Liabilities	$5.692M	$6.313M	$0.00
Total Liabilities	$12.27M	$11.76M	$580.0K
YoY Change	-72.6%	1927.24%	-56.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$128.1M	-$123.6M	-$7.094M
YoY Change	25.67%	1641.85%
Common Stock	$160.7M	$159.5M	$480.00
YoY Change	594.43%	33223441.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$32.61M	$35.91M	$12.70M
YoY Change
Total Liabilities & Shareholders Equity	$44.87M	$47.66M	$13.27M
YoY Change	2793.17%	259.08%	1085.18%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	-$4.540M	-$4.932M	-$11.13M
YoY Change	165.19%	-55.7%	1020.12%
Depreciation, Depletion And Amortization	$50.00K	$60.00K	$0.00
YoY Change
Cash From Operating Activities	-$2.980M	-$3.410M	-$1.280M
YoY Change	127.48%	166.41%	24.27%
INVESTING ACTIVITIES
Capital Expenditures	-$150.0K	-$70.00K	-$100.0K
YoY Change		-30.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$140.0K	-$70.00K	-$100.0K
YoY Change		-30.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	-10.00K
YoY Change		-100.0%	-100.94%
NET CHANGE
Cash From Operating Activities	-2.980M	-3.410M	-1.280M
Cash From Investing Activities	-140.0K	-70.00K	-100.0K
Cash From Financing Activities	0.000	0.000	-10.00K
Net Change In Cash	-3.120M	-3.480M	-1.390M
YoY Change	138.17%	150.36%	-4733.33%
FREE CASH FLOW
Cash From Operating Activities	-$2.980M	-$3.410M	-$1.280M
Capital Expenditures	-$150.0K	-$70.00K	-$100.0K
Free Cash Flow	-$2.830M	-$3.340M	-$1.180M
YoY Change	116.03%	183.05%	14.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	676000
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.66
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	813167	shares
CY2015Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6313000
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14696100	shares
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14516010	shares
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	753000
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	665202	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2224270	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.75
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14696100	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.61
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2094163	shares
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	611000
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	159472000
CY2015Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	116000
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3422000
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	35906000
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	151000
CY2015Q3	us-gaap	Long Term Debt LongTermDebt	6726000
CY2015Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	11000
CY2015Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	413000
CY2015Q3	us-gaap	Accrued Vacation Current AccruedVacationCurrent	70000
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	927000
CY2015Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	432000
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1135000
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-123567000
CY2015Q3	us-gaap	Liabilities Liabilities	11758000
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47664000
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	1000
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities Noncurrent BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent	2959000
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	654000
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	698000
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2475000
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	632000
CY2015Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2959000
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1706000
CY2015Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	6022000
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18000
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1825000
CY2015Q3	us-gaap	Assets Assets	47664000
CY2015Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7534000
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	558000
CY2015Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	253000
CY2015Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	274000
CY2015Q3	us-gaap	Assets Current AssetsCurrent	23359000
CY2015Q3	us-gaap	Goodwill Goodwill	15942000
CY2015Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	7534000
CY2015Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.4	pure
CY2015Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2692000
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1333000
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22026000
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1875000
CY2015Q3	pulm	Stock And Warrant Issued During Period Value New Issues StockAndWarrantIssuedDuringPeriodValueNewIssues	10000000
CY2015Q3	pulm	Accrued Clinical And Consulting Current AccruedClinicalAndConsultingCurrent	411000
CY2015Q3	pulm	Accrued Legal And Patent Current AccruedLegalAndPatentCurrent	106000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1425000
CY2014Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	63413042	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	732823	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	233500000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.08
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	188625	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	202604452	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	188625	shares
CY2014Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	63413042	shares
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	23142000
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	55000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-78794000
CY2014Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	36389000
CY2014Q4	us-gaap	Long Term Debt LongTermDebt	39703000
CY2014Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	35573000
CY2014Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	39703000
CY2014Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	31000
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	216000
CY2014Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	60000
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3544000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101936000
CY2014Q4	us-gaap	Liabilities Liabilities	44772000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1551000
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	43463000
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	3338000
CY2014Q4	us-gaap	Assets Assets	1551000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	470000
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	250000
CY2014Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	18000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	831000
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	380000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	451000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5508000
CY2014Q4	pulm	Preferred Stock Warrant Liability PreferredStockWarrantLiability	1309000
CY2014Q4	pulm	Temporary Equity Shares Issued Upon Conversion TemporaryEquitySharesIssuedUponConversion	4155539	shares
CY2014Q4	pulm	Accrued Clinical And Consulting Current AccruedClinicalAndConsultingCurrent	16000
CY2014Q4	pulm	Accrued Legal And Patent Current AccruedLegalAndPatentCurrent	44000
CY2015Q1	us-gaap	Bridge Loan BridgeLoan	350000
CY2015Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-2.5 reverse stock split
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7329000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-115.78
	pulm	Conversion Of Convertible Notes And Accrued Interest Into Common Stock ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock	43060000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	186792	shares
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	218000
	us-gaap	Net Income Loss NetIncomeLoss	-21588000
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-29195000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21627000
	us-gaap	Revenues Revenues	38000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	31000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7453000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	27000
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-59000
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	38000
	us-gaap	Share Based Compensation ShareBasedCompensation	195000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-620000
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	39000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-672000
	us-gaap	Operating Expenses OperatingExpenses	7491000
	us-gaap	Interest Expense InterestExpense	14754000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-218000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	6875000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5420000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-226000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2071000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-90000
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	6875000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	245000
	pulm	Net Income Loss Attributable To Common Stockholders Basic And Diluted NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted	-21627000
	pulm	Noncash Interest Expenses NoncashInterestExpenses	14754000
	pulm	Promissory Note Issuance Proceeds Allocated To Beneficial Conversion Feature PromissoryNoteIssuanceProceedsAllocatedToBeneficialConversionFeature	2256000
	pulm	Promissory Note Issuance Proceeds Allocated To Preferred Stock Warrants PromissoryNoteIssuanceProceedsAllocatedToPreferredStockWarrants	306000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9494000
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Basis Of Accounting BasisOfAccounting	<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>2. Basis of Presentation</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a going concern basis in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2015. For further information, refer to the financial statements and footnotes included in the Company’s annual financial statements for the fiscal year ended December 31, 2014, which are included in the Company’s current report on Form 8-K/A filed with the SEC on August 14, 2015.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Merger and Exchange Ratio</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Merger has been accounted for as a “reverse merger” under the acquisition method of accounting for business combinations with Pulmatrix Operating treated as the accounting acquirer of Ruthigen. The historical financial statements of Pulmatrix Operating have become the historical financial statements of the Company, or the combined company, and are included in this filing labeled Pulmatrix, Inc. As a result of the Merger, historical common stock, stock options and additional paid-in capital, including share and per share amounts, have been retroactively adjusted to reflect the equity structure of the combined company, including the effect of the Merger exchange ratio and the common stock par value of $0.0001 per share. See Note 5, “Merger,” for additional discussion of the Merger and the exchange ratio.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Reverse Stock Split</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> On June 15, 2015, following the Effective Time, the Company effected a 1-for-2.5 reverse stock split (the “Reverse Stock Split”) of its outstanding common stock, par value $0.0001 per share (“Company Common Stock”). The accompanying condensed consolidated financial statements and notes to the condensed consolidated financial statements, including the Merger exchange ratio (Note 5) applied to historical Pulmatrix Operating common stock and stock options unless otherwise noted, give retroactive effect to the Reverse Stock Split for all periods presented. The shares of Company Common Stock retained a par value of $0.0001 per share.</p> </div>
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-14557000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	151000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21631000
	dei	Entity Central Index Key EntityCentralIndexKey	0001574235
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.51
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1540388	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.69
	dei	Document Type DocumentType	10-Q
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y11M12D
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	Pulmatrix, Inc.
	us-gaap	Revenues Revenues	926000
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2291000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	2018	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.12
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	71323	shares
	dei	Trading Symbol TradingSymbol	PULM
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.3928	pure
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	2384	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5860758	shares
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y3M18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.12
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y7M6D
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	120000
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	3022000
	us-gaap	Net Income Loss NetIncomeLoss	-21631000
	pulm	Fair Value Adjustment On Derivative Liability FairValueAdjustmentOnDerivativeLiability	2291000
	pulm	Gain Loss On Conversion Of Convertible Notes GainLossOnConversionOfConvertibleNotes	-1170000
	pulm	Debt Instrument Unamortized Discount During Period DebtInstrumentUnamortizedDiscountDuringPeriod	-1847000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1888000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	801000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18724000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-24000
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	198000
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	3000
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	35573000
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-10000
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4248000
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	30422000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1161000
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	926000
	us-gaap	Share Based Compensation ShareBasedCompensation	4272000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1309000
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	20750000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	21575000
	us-gaap	Operating Expenses OperatingExpenses	19650000
	us-gaap	Interest Expense InterestExpense	731000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	9551000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	21518000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4721000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	821000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	151000
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	6910000
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	23772000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14929000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	4248000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	430000
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	9671000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	709000
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	4457000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	179000
	pulm	Operating Lease Agreement Amended Date OperatingLeaseAgreementAmendedDate	2015-10-27
	pulm	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Acquisition ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisition	24400	shares
	pulm	Noncash Rent Expense NoncashRentExpense	17000
	pulm	Net Income Loss Attributable To Common Stockholders Basic And Diluted NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted	-21631000
	pulm	Share Based Compensation Arrangements By Share Based Payment Award Options Assumed In Merger Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice	14.07
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M23D
	pulm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	10000000
	pulm	Noncash Interest Expenses NoncashInterestExpenses	533000
CY2015Q3	us-gaap	Interest Expense InterestExpense	220000
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-59.60
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	187044	shares
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-11134000
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11147000
CY2014Q3	us-gaap	Revenues Revenues	30000
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2594000
CY2014Q3	us-gaap	Share Based Compensation ShareBasedCompensation	50000
CY2014Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	655000
CY2014Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	13000
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	2624000
CY2014Q3	us-gaap	Interest Expense InterestExpense	7885000
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1929000
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	695000
CY2014Q3	pulm	Net Income Loss Attributable To Common Stockholders Basic And Diluted NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted	-11147000
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14654427	shares
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-4932000
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4932000
CY2015Q3	us-gaap	Revenues Revenues	651000
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4661000
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-51000
CY2015Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2441000
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	5312000
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2193000
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3119000
CY2015Q3	pulm	Net Income Loss Attributable To Common Stockholders Basic And Diluted NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted	-4932000

Files In Submission

Name	View Source	Status
R43.htm	Edgar Link	pending
0001193125-15-374719-index-headers.html	Edgar Link	pending
0001193125-15-374719-index.html	Edgar Link	pending
0001193125-15-374719.txt	Edgar Link	pending
0001193125-15-374719-xbrl.zip	Edgar Link	pending
d32697d10q.htm	Edgar Link	pending
d32697dex311.htm	Edgar Link	pending
d32697dex312.htm	Edgar Link	pending
d32697dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pulm-20150930.xml	Edgar Link	completed
pulm-20150930.xsd	Edgar Link	pending
pulm-20150930_cal.xml	Edgar Link	unprocessable
pulm-20150930_def.xml	Edgar Link	unprocessable
pulm-20150930_lab.xml	Edgar Link	unprocessable
pulm-20150930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PULM
Pulmatrix Inc Stock $pulm

2015 Q4 Form 10-Q Financial Statement

#000119312515374719 Filed on November 12, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM Pulmatrix Inc Stock $pulm

2015 Q4 Form 10-Q Financial Statement

#000119312515374719 Filed on November 12, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM
Pulmatrix Inc Stock $pulm